{'fraction_non_alphanumeric': 0.026450511945392493, 'fraction_numerical': 0.024744027303754267, 'mean_word_length': 5.9, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Additional Efficacy of Macrolide for Patients With Acute Deterioration of Interstitial Lung Disease Requiring Corticosteroid Pulse Therapy.

To the Editor: Acute deterioration of interstitial lung disease (AD-ILD) including acute or subacute idiopathic interstitial pneumonia (IIP) and secondary causes is a pathologic condition that manifests as rapid respiratory failure.1–5 Macrolides, which are known for their antibacterial, anti-inflammatory, and antifibrotic effects, have been found to be beneficial in patients with various lung diseases.6–11 These drugs have been reported to provide clinical benefit in not only patients with chronic airway inflammatory diseases, but also in patients with ILD including acute lung injury and idiopathic pulmonary fibrosis (IPF).6–10 However, few reports have clarified the clinical utility of macrolides in patients with AD-ILD.11 The retrospectively observational study was performed at Yokohama City University between 2014 and 2018 (approval number B171100003). The medical data of 97 patients requiring corticosteroid pulse therapy because of AD-ILD consisting of acute or subacute IIP, including acute exacerbation (AE) of